Karolinska Development AB KDEV

STO: KDEV | ISIN: SE0002190926   27/06/2025
1,032 SEK (+5,31%)
(+5,31%)   27/06/2025

30 juni 2025 · Karolinska Development divests shares in portfolio company OssDsign · Persbericht

27 juni 2025 · Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million · Persbericht

4 juni 2025 · Karolinska Development’s portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets · Persbericht

26 mei 2025 · Karolinska Development’s portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study · Persbericht

15 mei 2025 · Karolinska Development’s Annual General Meeting 2025 · Persbericht

13 mei 2025 · Karolinska Development’s portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US · Persbericht

7 mei 2025 · Karolinska Development’s portfolio company Umecrine Cognition presents data validating novel clinical scale in PBC at EASL 2025 · Persbericht

5 mei 2025 · Karolinska Development’s portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation · Persbericht

30 april 2025 · Karolinska Development portfolio company OssDsign will change CEO during second half of 2025 · Persbericht

30 april 2025 · Interim Report - January-March 2025 · Persbericht

7 april 2025 · Notice of Annual General Meeting in Karolinska Development AB (publ) · Persbericht

1 april 2025 · Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO · Persbericht

1 april 2025 · Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025 · Persbericht

21 maart 2025 · Karolinska Development Annual Report 2024 published · Persbericht

18 maart 2025 · Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study · Persbericht

13 maart 2025 · Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01 · Persbericht

12 maart 2025 · Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial · Persbericht

25 februari 2025 · Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01 · Persbericht

18 februari 2025 · Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface · Persbericht

14 februari 2025 · Year-end Report - January-December 2024 · Persbericht

Mijn selecties